Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Clarifying the concept of chronic kidney disease for non-nephrologists.

Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Fernandez-Fernandez B, Martin-Cleary C, Gracia-Iguacel C, Ortiz A.

Clin Kidney J. 2019 Feb 14;12(2):258-261. doi: 10.1093/ckj/sfz007. eCollection 2019 Apr.

2.

Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development.

Perez-Gomez MV, Martin-Cleary C, Fernandez-Fernandez B, Ortiz A.

Clin Kidney J. 2018 Aug;11(4):491-495. doi: 10.1093/ckj/sfy070. Epub 2018 Jul 31.

3.

Designing a Method with Physician Participation to Assess and Improve Quality of Healthcare in Otolaryngology.

Arce JM, Martín Cleary C, Cenjor C, Ramos Á, Ortiz A.

J Int Adv Otol. 2017 Apr;13(1):128-135. doi: 10.5152/iao.2017.2880.

4.

Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son".

Castillo-Rodríguez E, Pizarro-Sánchez S, Sanz AB, Ramos AM, Sanchez-Niño MD, Martin-Cleary C, Fernandez-Fernandez B, Ortiz A.

Toxins (Basel). 2017 Mar 23;9(4). pii: E114. doi: 10.3390/toxins9040114. Review.

5.

Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease.

Castillo-Rodriguez E, Fernandez-Prado R, Martin-Cleary C, Pizarro-Sánchez MS, Sanchez-Niño MD, Sanz AB, Fernandez-Fernandez B, Ortiz A.

Nephron. 2017;136(4):263-267. doi: 10.1159/000447649. Epub 2016 Oct 22. Review.

6.

Circulating CXCL16 in Diabetic Kidney Disease.

Elewa U, Sanchez-Niño MD, Mahillo-Fernández I, Martin-Cleary C, Belen Sanz A, Perez-Gomez MV, Fernandez-Fernandez B, Ortiz A.

Kidney Blood Press Res. 2016;41(5):663-671. Epub 2016 Sep 26.

7.

PCSK9 in diabetic kidney disease.

Elewa U, Fernández-Fernández B, Mahillo-Fernández I, Martin-Cleary C, Sanz AB, Sanchez-Niño MD, Ortiz A.

Eur J Clin Invest. 2016 Sep;46(9):779-86. doi: 10.1111/eci.12661. Epub 2016 Aug 9.

PMID:
27438893
8.

Targeting inflammation in diabetic kidney disease: early clinical trials.

Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Zheng B, Martín-Cleary C, Ruiz-Ortega M, Ortiz A, Fernandez-Fernandez B.

Expert Opin Investig Drugs. 2016 Sep;25(9):1045-58. doi: 10.1080/13543784.2016.1196184. Epub 2016 Jun 13. Review.

PMID:
27268955
9.

Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants.

Cannata-Ortiz P, Gracia C, Aouad Y, Barat A, Martinez-Gonzalez MA, Rossello G, Martin-Cleary C, Fernández-Fernández B, Requena L, Ortiz A.

Diagn Pathol. 2016 Jan 8;11:2. doi: 10.1186/s13000-016-0453-y.

10.

Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade.

Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M, Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B.

J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. Review.

11.

CKD hotspots around the world: where, why and what the lessons are. A CKJ review series.

Martín-Cleary C, Ortiz A.

Clin Kidney J. 2014 Dec;7(6):519-23. doi: 10.1093/ckj/sfu118. Epub 2014 Nov 13.

12.

Designing drugs that combat kidney damage.

Ramos AM, González-Guerrero C, Sanz A, Sanchez-Niño MD, Rodríguez-Osorio L, Martín-Cleary C, Fernández-Fernández B, Ruiz-Ortega M, Ortiz A.

Expert Opin Drug Discov. 2015 May;10(5):541-56. doi: 10.1517/17460441.2015.1033394. Epub 2015 Apr 3. Review.

PMID:
25840605
13.

Translational value of animal models of kidney failure.

Ortiz A, Sanchez-Niño MD, Izquierdo MC, Martin-Cleary C, Garcia-Bermejo L, Moreno JA, Ruiz-Ortega M, Draibe J, Cruzado JM, Garcia-Gonzalez MA, Lopez-Novoa JM, Soler MJ, Sanz AB; Red de Investigacion Renal (REDINREN) and Consorcio Madrileño para investigación del fracaso renal agudo (CIFRA).

Eur J Pharmacol. 2015 Jul 15;759:205-20. doi: 10.1016/j.ejphar.2015.03.026. Epub 2015 Mar 24. Review.

PMID:
25814248
14.

Bicarbonate therapy, phosphate binders, and risk for vascular calcification.

Fernandez-Fernandez B, Martin-Cleary C, Ortiz A.

Kidney Int. 2014 Nov;86(5):1056. doi: 10.1038/ki.2014.191. No abstract available.

15.

Mitochondria-targeted therapies for acute kidney injury.

Tábara LC, Poveda J, Martin-Cleary C, Selgas R, Ortiz A, Sanchez-Niño MD.

Expert Rev Mol Med. 2014 Aug 8;16:e13. doi: 10.1017/erm.2014.14. Review. Erratum in: Expert Rev Mol Med. 2014;16:e14.

PMID:
25104110
16.

CXCL16 in kidney and cardiovascular injury.

Izquierdo MC, Martin-Cleary C, Fernandez-Fernandez B, Elewa U, Sanchez-Niño MD, Carrero JJ, Ortiz A.

Cytokine Growth Factor Rev. 2014 Jun;25(3):317-25. doi: 10.1016/j.cytogfr.2014.04.002. Epub 2014 May 2. Review.

PMID:
24861945
17.

TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease.

Poveda J, Tabara LC, Fernandez-Fernandez B, Martin-Cleary C, Sanz AB, Selgas R, Ortiz A, Sanchez-Niño MD.

Front Immunol. 2013 Dec 10;4:447. doi: 10.3389/fimmu.2013.00447. Review.

18.

Progress in the development of animal models of acute kidney injury and its impact on drug discovery.

Sanz AB, Sanchez-Niño MD, Martín-Cleary C, Ortiz A, Ramos AM.

Expert Opin Drug Discov. 2013 Jul;8(7):879-95. doi: 10.1517/17460441.2013.793667. Epub 2013 Apr 29. Review.

PMID:
23627598
19.

Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.

Elewa U, Sanchez-Niño MD, Martin-Cleary C, Fernandez-Fernandez B, Egido J, Ortiz A.

Int Urol Nephrol. 2012 Dec;44(6):1731-44. doi: 10.1007/s11255-012-0271-4. Epub 2012 Sep 11. Review.

PMID:
22965378
20.

Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?

Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Barat A, Martín-Cleary C, Egido J.

BMC Nephrol. 2012 Apr 25;13:21.

Supplemental Content

Loading ...
Support Center